Post-marketing, observational, prospective, multi-center, non-randomized, single-arm registry that will include all patients who receive the Inspiron™ EVO stent at participating sites and meet the eligibility criteria.
Up to 2,000 patients are expected to be enrolled across 12 research sites in Brazil. Participants' demographic, procedural, and follow-up data will be collected for up to 12 months in this study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI).
Individuals who provide consent and are willing to comply with the follow-up protocol.
Individuals who received treatment with the Inspiron™ EVO Stent.
Individuals with lesions ≥ 30 mm in length (Subprotocol 1).
Individuals with significantly calcified coronary lesions (moderate to severe according to the ACC/AHA classification B1, B2, or C), with or without indication for lesion preparation techniques (Subprotocol 2).
Individuals with multivessel coronary artery disease (≥2 affected coronary vessels, with at least one vessel of small diameter ≤2.5 mm) (Subprotocol 3).
Individuals included in Subprotocol 1, 2, or 3. The evaluated segment must be accessible to the IVUS (Intravascular Ultrasound) catheter (Subprotocol 4).
You may not be if
Lesions in saphenous vein grafts or internal mammary grafts.
Contraindication to the use of a drug-eluting stent.
Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.